Utilizes clinical-grade next-generation sequencing (NGS) combined with population-specific polygenic risk scores (PRS) to accurately diagnose elusive genetic disorders. Our newborn screening panels employ tandem mass spectrometry to detect inborn errors of metabolism (IEMs), such as phenylketonuria (PKU) and MCAD deficiency, within days of birth. For complex cases, our comprehensive rare disease panels screen for ~5,000 monogenic disorders, incorporating Saudi-specific variant databases to improve diagnostic yield. This approach reduces the diagnostic odyssey from years to weeks, enabling early, targeted interventions for conditions like spinal muscular atrophy (SMN1/SMN2) and lysosomal storage disorders.
Take the first step toward better health — send us your inquiry today and discover personalized insights for a healthier future.
"Frankly speaking, the experience was the first time I dealt with them. They were very quick to respond. They made an appointment for me at home on their appointment, and there was no delay. The result was not delayed exactly as they said, 7 days. God willing, I wish them success, Lord."
© Copyright 2025 Novo Genomics. All Rights Reserved